Phase I Clinical Study of MPDL3280A in Patients with Advanced Solid Tumors
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Atezolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 01 Feb 2018 Planned End Date changed from 31 Mar 2018 to 1 Mar 2021.
- 16 Dec 2016 Pooled analysis results of this trial and other (NCT01375842 and NCT02108652) published in the Clinical Pharmacology and Therapeutics
- 01 Jul 2016 Results published in the Investigational New Drugs